natgillin/translations-raw huggingface dataset:
The solid oral extended release pharmaceutical dosage form of anyone of items 60, 62, 64, 66, 68, 71-78, 81, 84 and 85, wherein the extended release matrix formulation after having been stored at 25 °C and 60 % relative humidity (RH) for at least 1 month provides a dissolution rate, when measured in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid without enzymes (SGF) at 37° C, characterized by the percent amount of active agent released at 1, 4 and 12 hours of dissolution that deviates no more than about 15 % points from the corresponding in-vitro dissolution rate of a reference formulation prior to storage. 
Oralni farmaceutski oblik doziranja u krutom stanju sa produljenim otpuštanjem prema bilo kojem od zahtjeva 1 do 13, naznačen time da je gustoća formulacije matrice sa produljenim otpuštanjem jednaka ili manja od oko 1.20 g/cm?, poželjno jednaka ili manja od oko 1.19 g/em'. Oralni farmaceutski oblik doziranja u krutom stanju sa produljenim otpuštanjem prema bilo kojem od zahtjeva 1 do pri čemu formulacija matrice sa produljenim otpuštanjem nakon što je pohranjena na 25 *C 1 60 % relativne vlažnosti (RH) tijekom najmanje 1 mjeseca daje brzinu otapanja, koja kada je mjerena na USP aparatu 1 (košara) kod 100 okr/min. u 900 ml simulirane želučane tekućine bez enzima (SGF) na 37?
A type II crystal of 1-(2'-cyano-2'-deoxy-B-D-arabinofuranosyl)cytosine monohydrochloride having characteristic peaks at 6.4°, 12.6°, 17.3°, and 21.7° as diffraction angles (2θ ± 0.1°) measured by powder X-ray diffraction, and having a melting point of 192°C to 196°C. 
Tip II kristala 1-(2'-cijano-2'-deoksi-B-D-arabinofuranozil)citozin monohidroklorida, naznačen time da ima karakteristične vrhove na 6.4°, 12.6°, 17.3° i 21.7° kao difrakcijske kutove (2#6 0,1°) izmjereno rendgenskom difrakcijom praha, i koji ima točku tališta od 192°C do 196°C.
The composition of claim 9 which is an aqueous solution and wherein the fatty acid is oleic acid. 
Kompozicija prema patentnom zahtjevu 14, naznačena time što je to vodena otopina i masna kiselina je oleinska kiselina.
wherein in case of a failure of the functionality of the home database, the requesting entity requests the visitor database for the information specific of the User Equipment. 
u slučaju onesposobljenosti funkcije polazne baze podataka (14), tražitelj usluge (12) od baze podataka o posjetiteljima (11) traži podatke koji su specifični za korisnikov uređaj (20).
Though highly efficient, known mixing members have the major drawback of being relatively difficult to clean, on account of the ice-cream accumulating in the cavities housing the helical springs and scrapers, with all the obvious problems this involves. 
Premda su vrlo učinkoviti, poznati članci za miješanje imaju veći nedostatak da su relativno teški za čišćenje zbog razloga što se sladoled nakuplja u šupljinama u kojima su smještene spiralne opruge i strugala sa svim očitim problemima koje ovo uključuje.
wherein L represents a leaving group, with an optionally substituted N-benzyl-4-piperidone 
(m) gdje L predstavlja odlazeću skupinu, s N-benzil-4-piperidonom koji može biti po izboru supstituiran
dividing said first fine fraction further by sieving or air classification into a second coarse fraction, a second fine fraction and a third fine fraction, said second coarse fraction comprising a B-glucan concentrate having a B-glucan content of 45 to 60%, said second fine fraction comprising a starch concentrate having a starch content of more than 80%, and said third fine fraction comprising a protein concentrate having a protein content of more than 30%, preferably 50 to 80%. 
(d) dijeljenje te prve fine frakcije dalje prosijavanjem ili klasifikacijom zrakom u drugu grubu frakciju, drugu finu frakciju 1 treću finu frakciju, ta druga gruba frakcija sadrži koncentrat B-glukana sa sadržajem B-glukana od 45 do 60%, druga fina frakcija sadrži koncentrat škroba sa sadržajem škroba većim od 80%, 1 treća fina frakcija sadrži koncentrat proteina sa sadržajem proteina većim od 30%, poželjno 50 do 80%.
a processor (212) configured to interpret at least one marking in the image; 
i procesor (212), konfiguriran tako da interpretira barem jednu oznaku u slici;
The oil according to claim 3 wherein said cereal flavourings are selected from the following flavourings: barley, oats, corn, rice, rye, sorgum, wheat, and millet, and wherein said fruit flavorings are selected from the group consisting of walnut, almond, hazelnut, blackcurrant, apricot, peach, avocado, cherry, watermelon, melon, blueberry, orange and vanilla. 
Ulje prema zahtjevu 5, naznačeno time, da su spomenuti žitni i voćni aromatski dodaci odabrani između sljedećih: ječam, zob, kukuruz, riža, raž, sijerak, pšenica, proso, orah, badem, lješnjak, crni ribiz, marelica, breskva, avokado, višnja, lubenica, dinja, kupina, naranča i vanilija.
It is clear that the greater the density of ribs (3, 4) distributed over the length of the core 1, the smaller the longitudinal size a of the ribs and the greater the resistance to deformation of the core 1. 
Jasno je da što je veća gustoća nabora (3, 4) duž jezgre 1, a manja dužna mjera a nabora, da je otpornost jezgre 1 na deformaciju, samim time, veća.
At least one of the detaching means can be designed to carry out a rotational detaching movement. 
Barem jedno od sredstava za odvajanje može biti predviđeno da izvodi rotacijsko kretanje kod odvajanja.
The device according to claim 4, wherein the compartment cover has an outer contour which corresponds to an inner contour of the circumferential web such that the compartment cover is disposed inside the compartment. 
Uređaj prema zahtjevu 4, naznačeno time da poklopac odjeljka (77) ima vanjsku konturu koja odgovara unutarnjoj konturi mreže (74), tako da poklopac odjeljka (77) leži unutar odjeljka (72).
The ink was applied in the form of a screen-printed patch onto a standard coated paper (80 g/m2), and the so imprinted paper was laid, while still wet, onto the engraved magnetic plate described above, exposing the back side of the imprinted paper to the engraved top side of the magnetic plate. 
Tinta se nanosi u obliku površine otisnute zaslonom na standardni premazani papir (80 g/m*) tako da se otisnuti papir, dok je još uvijek vlažan, postavi na gore opisanu ugraviranu magnetsku ploču izlaganjem donje strane otisnutog papira ugraviranoj gornjoj strani magnetske ploče.
A combination of a proteasome inhibitor, wherein said proteasome inhibitor is bortezomib, and a histone deacetylase inhibitor wherein said histone deacetylase inhibitor is compound No. 
Kombinacija, naznačena time, da sadrži inhibitor proteasoma, pri čemu je navedeni inhibitor proteasoma bortezomib, te inhibitor histonske deacetilaze, pri čemu je navedeni inhibitor histonske deacetilaze spoj br.
A method for producing a foamed moulded product, characterised in that the method comprises the steps of: 
Postupak dobivanja pjenastog oblikovanog proizvoda, naznačen time što se postupak sastoji u koracima: i)
A polypeptide signal sequence, comprising a modified fragment of human immunoglobulin heavy chain binding protein (Bip), wherein the modified fragment of human immunoglobulin heavy chain binding protein (Bip) consists of the amino acid sequence of SEQ ID NO: 20; the amino acid sequence of SEQ ID NO: 21; the amino acid sequence of SEQ ID NO: 22; or the amino acid sequence of SEQ ID NO: 23. 
Polipeptidna signalna sekvenca, koja sadrži modificirani fragment ljudskog imunoglobulinskog teškog lanca vezujućeg proteina (Bip), naznačena time da modificirani fragment ljudskog imunoglobulinskog teškog lanca vezujućeg proteina (Bip) obuhvaća aminokiselinsku sekvencu SEQ ID NO: 20; aminokiselinsku sekvencu SEQ ID NO: 21; aminokiselinsku sekvencu SEQ ID NO: 22; ili aminokiselinsku sekvencu SEQ ID NO: 23.
to form a composition; shaping the composition to form an extended release matrix formulation; and curing said extended release matrix formulation comprising at least a curing step wherein said polyethylene oxide at least partially melts. 
(b) oblikovanje sastava kako bi se formirala formulacija matrice s produljenim otpuštanjem; i (c) stvrdnjavanje navedene formulacije matrice s produljenim otpuštanjem koje sadrži barem korak stvrdnjavanja gdje se navedeni polietilen oksid barem djelomično rastopi.
Myelosuppression, a reduction in blood cell levels and in the generation of new blood cells in the bone marrow, is also a common, toxic effect of many standard chemotherapeutic drugs. 
Mijelosupresija, redukcija razine stanica u krvi i u generairanju novih krvnih stanica u koštanoj srži, je također poznata, toksični efekt mnogih standardnih kemoterapijskih lijekova.
Nicotinic acid is also one of the oldest used drugs for the treatment of dyslipidemia. 
Nikotinska kiselina je također jedan od najstarije korištenih lijekova za liječenje dislipidemije.
A product comprising (a) a B2 agonist as defined in any one of claims 1 and 3 to 7 and (b) an antagonist of M3 muscarinic receptors as defined in claim 1 or 2, as a combined preparation for simultaneous, concurrent, separate or sequential use in the treatment of a patient suffering from or susceptible to a respiratory disease as defined in claim 11 or 12, while producing less heart side-effects than a therapeutically equivalent combination of tiotropium with the B2 agonist. 
. Proizvedeni lijek, naznačen time, da sadrži (a) inhibitor PDE4 kako se definira u bilo kojem od patentnih zahtjeva 113 do 6 i (b) antagonist muskarinskih receptora M3 kako se definira u patentnom zahtjevu 1 ili 2, u obliku kombiniranog pripravka za istovremenu, paralelnu, odvojenu ili sekvencijsku primjenu u liječenju bolesnika koji boluje od ili je osjetljiv na bolest dišnih putova koja reagira na M3 antagonizam.
The use according to enbodiment 41, wherein the patient being treated has previously been refractive to treatment with IGF-1, IGF-2 or variants of IGF-1 or IGF-2, an anti-myostatin antibody, a myostatin propeptide, a myostatin decoy protein that binds ActRIIB but does not activate it, a beta 2 agonist, a Ghrelin agonist, a SARM, GH agonists/mimetics or follistatin. 
Protutijelo za uporabu prema zahtjevu 24, naznačeno time, da je pacijent koji se liječi, bio prethodno refraktivan na liječenje s IGF-1, IGF-2 ili s varijantama od IGF-1 ili IGF-2, protutijelom anti-miostatin, miostatin- HR P20171870 T1 propeptidom, miostatin-decoy-proteinom koji veže ActRIIB, ali ga ne aktivira, beta 2-agonistom, Ghrelin-agonistom, SARM-om, GH-agonistima/mimeticima ili folistatinom.
The compound according to claims 1, wherein Y4 is selected from the group consisting of S-O-, S=O, O--S=O, and O=S=O and Y1, Y2, Y3, and Y5 are S. 
Spoj prema patentnom zahtjevu 1, naznačen time, da se Y2 odabire iz skupine koja se sastoji od S-0', S=0, O" -S=01 O=S=0, a Y,,Y2,Yal Y; jesu S.
The compound for use of claim 10, wherein the compound is used in a therapeutically effective amount ranging from 0.1 mg/kg to 300 mg/kg. 
Spoj za uporabu u skladu s patentnim zahtjevom 9, naznačen time, da se spoj upotrebljava u liječenju sistemskog eritematoznog lupusa ili lupus nefritisa.
wherein R1, R2, R3, R4, R5, R8, R7, R8 and X have the meanings assigned to them in claim 1 with a compound of the formula G═Y, wherein G represents the alkyl, acyl, phosphoryl or sulfonyl group to be incorporated and Y is a suitable nucleofuge, in the presence of at least one equivalent of a base. 
Formula (A) gdje R!, RR", R', RR. R', Rši X imaju značenja koja su im naznačena u zahtjevu 1, sa spojem formule G -Y, gdje G predstavlja alkil, acil, fosforil ili sulfonil skupinu koja se treba pripojiti, a Y je pogodna nukleofuga, u prisutnosti barem jednog ekvivalenta baze.
a step of amidating the compound of the formula (3) by reacting with 2-aminoethanol (2): (in the formula, Me represents methyl and R1 represents lower alkyl). 
[image] (u formuli Me predstavlja metil i R1 predstavlja nerazgranati ili razgranati C1-6alkil).
The compound of claim 12 according to formula 30: or a salt thereof. 
Spoj iz patentnog zahtjeva 1 u skladu sa formulom 30:
A therapeutic food composition comprising heat moisture treated starch for use in the treatment or prevention of hypoglycaemia. 
Terapeutski prehrambeni pripravak koji sadrži škrob tretiran toplinom 1 vlagom za upotrebu u liječenju ili prevenciji hipoglikemije.
Its activity has also been evaluated in vitro at minimum concentrations (mcg/m1) on Gram+bacteria, such as Staphylococcus aureus or Enterococcus faecalis, as well as at higher concentrations on Gram- bacteria, such as Escherichia coli, Salmonella, Enterobacter aerogenes, Enterobacter cloacae or Pseudomonas aeruginosa. 
Njegovo djelovanje određeno je također i u in vitro uvjetima pri minimalnim koncentracijama (mcg/ml) na Gram+ bakterijama, kao što su Staphylococcus aureus ili Enterococcus Jaecalis, te u većim koncentracijama na Gram- bakterijama poput Escherichia coli, Salmonella, Enterobacter aerogenes, Enterobacter cloacae ili Pseudomonas aeruginosa.
is an optionally substituted C1-6 alkyl group, an optionally substituted phenyl group, or an optionally substituted 5- to 7-membered heterocyclic group which has 1 or 2 nitrogen atom(s) or sulfur atom(s), or and R2 form, together with the nitrogen atom to which they are attached, an optionally substituted pyrrolidinyl group or an optionally substituted piperidinyl group; 
R* je po izboru supstituirana C;.4 alkil skupina, po izboru supstituirana fenil skupina, ili po izboru supstituirana 5- do 7- člane heterociklička skupina koja ima 1 ili 2 atoma dušika ili atom(e) sumpora, ili R! i R* oblik, zajedno s atomom dušika na kojeg su vezani, po izboru supstituiranu pirolidinil skupinu ili po izboru supstituiranu piperidinil skupinu;
While these devices have been useful, these prior art devices can be difficult to clean, use and store unused products, especially, when preparing smaller batches. 
I dok su ti uređaji vrlo korisni, uređaji starijeg datuna teško se čiste, koriste i pohranjuju neiskorištene proizvode, posebno kada se pripremaju manje količine.
This application claims priority to European Patent Application No. 
11.07.2018. Broj europske prijave patenta:
The process of creasing is applied on the splices of the side walls, i.e. within the box's storage part and on the lid. 
Proces presavijanja se izvršava na spojevima bočnih zidova, odnosno unutar spremišnog dijela kutije i na poklopcu.
water in an amount from 10.0 to 40.0% by weight of the composition, at least a lower alkanol in an amount from 60 to 80% by weight of the composition. 
C) vode u količini od 10,0 do 40,0 % masenog udjela pripravka, d) najmanje nižeg alkanola u količini od 60 do 80 % masenog udjela pripravka.
The anti-a5B1 antibody for use according to claim 12, wherein the VEGF antagonist can be competitively inhibited from binding to human VEGF by bevacizumab, wherein the VEGF antagonist is optionally bevacizumab. 
Integrinsko protutijelo anti-a5B1 za uporabu prema zahtjevu 12, naznačeno time, da se VEGF-antagonist može konkurentno sprečavati od spajanja na humani VEGF pomoću bavacizumaba, pri čemu je VEGF-antagonist opcijski bevacizumab.
A method of treating Hepatitis C viral infection in a mammal comprising administering to said mammal a therapeutically effective amount of the crystalline compound of formula (1) according to claim 9 or the sodium salt of the compound of formula (1) according to claim 2, or mixtures thereof. A method of treating Hepatitis C viral infection in a mammal comprising: preparing a pharmaceutical composition by a process comprising combining the sodium salt of claim 2, 3 or 4, with at least one pharmaceutically acceptable carrier or diluent; and 
Farmaceutski sastav prema zahtjevu 9, naznačen time, da je u sastavu prisutno najmanje 50% natrijeve soli spoja formule (1) u obliku kristalnog spoja prema zahtjevu 2, 3, 4, 5, 6 ili 7. 11. Uporaba natrijeve soli od spoja formule (1) prema zahtjevu 1, naznačena time, da je za proizvodnju lijeka za liječenje virusne hepatitis C infekcije kod sisavaca.
The pharmaceutical dosage form according to claim 7, which is for oral, intravenous, intraperitoneal, transdermal, intrathecal, intramuscular, intranasal, transmucosal, subcutaneous, or rectal administration. 
Farmaceutski oblik doziranja za uporabu za sprječavanje ili liječenje boli prema bilo kojem od zahtjeva 7 do 10, naznačen time da je za oralnu, intravensku, intraperitonealnu, transdermalnu, intratekalnu, intramuskularnu, intranazalnu, transmukoznu, potkožnu ili rektalnu primjenu.
Besides the release rate, also the lag time is influenced by the thickness of the second layer. 
Uz brzinu otpuštanja debljina drugog sloja također utječe na vrijeme kašnjenja.
The layers are separated, and the aqueous portion is carefully acidified with 5 N HCl to about pH 3 - 4. 
Slojeve se razdvoji, a vodeni dio pažljivo zakiseli s 5 N HCI do otprilike pH 3-4.
or coupling a compound of formula 4 with suitable fluorinating reagents selected from potassium fluoride or tetrabutylammonium fluoride, to afford compounds of formula I wherein the substituent R is hydrogen and, if desired, converting the compound obtained into pharmaceutically acceptable acid addition salts or into compounds of formula I, wherein R is tritium 
S prikladnim reagensima za fluorinaciju odabranim od kalijeva fluorida ili tetrabutilamonijevog fluorida, kako bi se stvorili spojevi formule I pri čemu supstituent R je vodik, te ako je poželjno, pretvaranje dobivenog spoja u farmaceutski prihvatljive kiselinske adicijske soli ili u spojeve formule I pri čemu je R tricij, reakcija spoja formule I d) u kojoj je R vodik,
a protein-binding segment that interacts with a Cas9 polypeptide, wherein the protein-binding segment comprises two complementary stretches of nucleotides that hybridize to form a double stranded RNA (dsRNA) duplex, and wherein said two complementary stretches of nucleotides are covalently linked by intervening nucleotides; 
(ii) segment koji veže protein i koji međudjeluje s navedenim kimernim proteinom Cas9, pri čemu segment koji veže protein obuhvaća dva komplementarna odsjeka nukleotida koji hibridiziraju za tvorbu dvostruke RNK strukture (AdsRNK)-dupleks, gdje se navadeno stavljanje u doticaj provodi in vitro ili u stanici ex vivo.
The method of any of claims 1 to 11, wherein the pharmaceutical composition comprising a CD19xCD3 bispecific single chain antibody construct is to be administered by continuous infusion for at least four weeks followed by a 2-week treatment-free interval. 
Konstrukt namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 8, naznačen time što farmaceutski pripravak koji sadrži CD19xCD3 bispecifično jednolančano protutijelo kao konstrukt treba primjenjivati kontinuiranom infuzijom najmanje četiri tjedna, za čim slijedi dvotjedni interval bez liječenja.
Assessment of the plasma levels of estriol 
Datum podnošenja europske prijave patenta:
and is unsubstituted or substituted. A pharmaceutical composition according to claim 1, wherein the HDAC inhibitor is selected from the following compounds and pharmaceutically acceptable salts thereof: 
Farmaceutski sastav prema bilo kojem zahtjevu od 1 do 6, naznačen time, da je molarni odnos arginina prema spomenutom HDAC inhibitoru najmanje 0,5.
reacting the trifluoroacetyl glatiramer acetate with aqueous piperidine to form a solution of aqueous glatiramer acetate; and 
reagiranje trifluoroacetil glatiramer acetata s vodenim piperidinom da se formira otopina glatiramer acetata; i
A rotor assembly according to claim 5, wherein the deformation comprises a protrusion and an oppositely-located indentation such as a punch mark. 
Sklop rotora prema zahtjevu 1, naznačen time da deformacija sadrži izbočinu i nasuprotno smješteno udubljenje kao što je oznaka za štancanje (55a)-d)).
The coarse fraction was a B-glucan concentrate having a B-glucan content of 52%, a protein content of 15%, a starch content of less than 16%, a fat content of less than 3%, and a volume-average particle size of 80 to 120 um, and 95% of the particles were between 20 and 500 um. This B-glucan concentrate was a light, almost white powder. Example 4B 
Koncentrat škroba na bazi zobi, naznačen time što sadržaj škroba je veći od 80%, sadržaj proteina je manji od 15%, poželjno manji od 10%, sadržaj masti je manji od 2.5%, poželjno manji od 1%, volumno-prosječna veličina čestica je 12 do 15 um i barem 95% čestica je između 11210 um,i dobiva se iz koraka (d) prema zahtjevu 1.
separating the trans-(-)-A9-tetrahydrocannabinol and the trans-(+)-A9-tetrahydrocannabinol from the alcoholic-caustic phase; and 
separacije trans-(-)-A9-tetrahidrokanabinola i trans-(+)-A9-tetrahidrokanabinola od alkoholno-kaustične faze; i
A method according to claim 13 wherein the infection of the plant is caused by a nematode or a fungus. 
Metoda temeljem zahtjeva 13 gdje je zaraza biljke uzrokovana nematodom ili fungusom.
is either free of amino acids or comprises one or more amino acids in a (collective) concentration of at most 0.1 mM; and 
ne sadrži aminokiseline ili sadrži jednu ili više aminokiselina u (zajedničkoj) koncentraciji najviše od 0.1 mM: i *
less than or equal to 4.6% by weight of Compound (1), or a pharmaceutically acceptable salt thereof: 
spoj (1) ili njegovu farmaceutski prihvatljivu sol: [image] u količini od 4,6% po masi ili manjoj;
After column chromatography on silica (5%-15% methanol in dichloromethane), compound 52 was obtained as an orange oil. 
Nakon kromatografije na stupcu silikagela (5%-15% metanol u diklormetanu), dobiva se spoj 52 kao narančasto ulje. a
A pharmaceutical composition comprising a compound of any one of clauses 1-32, or a stereoisomer or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent or excipient. 
Farmaceutski preparat koji sadrži spoj prema patentnom zahtjevu 1, ili njegovu farmaceutski prihvatljivu sol, i farmaceutski prihvatljiv nosač, razblaživač ili ekscipijens.
The isolated antibody or antigen binding fragment thereof of claim 1, wherein said antibody is a human antibody. 
14. Anti-TSLP ljudsko protutijelo iz patentnog zahtjeva 1, pri čemu je navedeno anti-TSLP ljudsko protutijelo monoklonsko protutijelo.
The formulation according to any of claims 1 to 13, which is for subcutaneous administration. 
Formulacija prema zahtjevu 10 ili 11, naznačena time da je za potkožno davanje.
The packaging and the device for manual rolling of cigarettes as claimed in Claims 1 and 2, characterized in that variously shaped clamps may be arranged instead of the lugs (1f) and openings (1a'). 
Pakiranje 1 uređaj za ručno motanje cigareta, prema zahtjevu 1 i 2, naznačen/o time, da umjesto uha (1f) i otvora (1a), mogu se rasporediti spone različitih oblika.
n is an integer from 4 to 50; and m is integer from 1 to 3, wherein the blood-brain barrier agent comprises a polypeptide sequence having at least 80% sequence identity to: L-R-V-R-L-A-S-H-L-R-K-L-R-K-R-L-L-R-D-A (SEQ ID NO:13), for use in treating brain disorder, in particular wherein the brain disorder is chosen from: meningitis, epilepsy, multiple sclerosis, neuromyelitis optica, late-stage neurological trypanosomiasis, Parkinson's, progressive multifocal leukoencephalopathy, De Vivo disease, Alzheimer's disease, HIV Encephalitis, and cancer. 
Kompleks, ili njegova farmaceutski prihvatljiva sol, koji sadrži biološki aktivno sredstvo povezano s peptidom nosačem, pri čemu peptid nosač sadrži sekvencu: X, - [B]y pri čemu: X je hidrofilna amino kiselina;B je sredstvo za krvno-moždanu barijeru;n je cijeli broj od 4 do 50; i m je cijeli broj od 1 do 3,pri čemu sredstvo za krvno-moždanu barijeru sadrži polipeptidnu sekvencu koja ima barem 80% identičnosti sekvence sa: L-R-V-R-L-A-S-H-L-R-K-L-R-K-R-L-L-R-D-A (SEQ ID NO:13), naznačen time da je za liječenje poremećaja mozga, naročito pri čemu je poremećaj mozga odabran od: meningitisa, epilepsije, multiple skleroze, optičkog neuromijelitisa, kasnog stupnja neurološke tripanosomijaze, Parkinsonove, progresivne multifokalne leukoencefalopatije, De Vivo bolesti, Alzheimerove bolesti, HIV encefalitisa, i raka.